Research Abstract
Our primary interest is in the use of novel agents in the therapy of Hodgkin's disease and Non-Hodgkin's Lymphoma. Specific interests include the therapy of systemic lymphomas which have spread to the central nervous system; prophylaxis of patients at high risk of future CNS involvement; and trials of novel single agents in the therapy of relapsed lymphoma patients.